DiaSorin S.p.A. (OTCMKTS:DSRLF – Get Free Report) gapped up prior to trading on Monday. The stock had previously closed at $84.12, but opened at $92.00. DiaSorin shares last traded at $92.00, with a volume of 226 shares.
Analyst Upgrades and Downgrades
Several research firms have recently issued reports on DSRLF. Deutsche Bank Aktiengesellschaft restated a “sell” rating on shares of DiaSorin in a report on Tuesday, August 4th. BNP Paribas Exane cut shares of DiaSorin from a “neutral” rating to an “underperform” rating in a research note on Tuesday, July 7th. UBS Group downgraded shares of DiaSorin from a “hold” rating to a “sell” rating in a research report on Wednesday, August 12th. Finally, Zacks Research raised shares of DiaSorin from a “strong sell” rating to a “hold” rating in a research report on Friday, October 2nd. Two research analysts have rated the stock with a Hold rating and three have given a Sell rating to the stock. According to MarketBeat.com, DiaSorin currently has an average rating of “Strong Sell”.
View Our Latest Analysis on DiaSorin
DiaSorin Price Performance
The stock has a 50-day moving average of $85.86 and a 200 day moving average of $79.20.
DiaSorin Company Profile
DiaSorin S.p.A. is an Italian company specializing in in vitro diagnostics, with a focus on immunodiagnostics and molecular diagnostics. Its products are used by hospitals, clinical laboratories and healthcare providers to support the detection, diagnosis and monitoring of a range of diseases and medical conditions.
The company’s portfolio includes automated immunoassay systems, reagents and diagnostic tests marketed under the LIAISON family, as well as molecular diagnostic platforms and assays.
Recommended Stories
- Five stocks we like better than DiaSorin
- Comfort Systems Earnings: AI Slowdown or More Growth Ahead?
- Bristol Myers Squibb’s Cancer Breakthrough Could Have Implications Beyond Its Own Stock
- 5 Beaten-Down Growth Stocks Trading Like Value Plays as Cash Chases Mega-Caps
- Anthropic’s IPO Filing Reveals a Massive Opportunity for AI Infrastructure Giants
Receive News & Ratings for DiaSorin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DiaSorin and related companies with MarketBeat.com's FREE daily email newsletter.
